185 related articles for article (PubMed ID: 18398749)
21. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Yang TM; Barbone D; Fennell DA; Broaddus VC
Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992
[TBL] [Abstract][Full Text] [Related]
22. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
[TBL] [Abstract][Full Text] [Related]
23. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
[TBL] [Abstract][Full Text] [Related]
24. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
25. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
[TBL] [Abstract][Full Text] [Related]
27. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.
Dengler MA; Weilbacher A; Gutekunst M; Staiger AM; Vöhringer MC; Horn H; Ott G; Aulitzky WE; van der Kuip H
Cell Death Dis; 2014 Jan; 5(1):e1013. PubMed ID: 24457957
[TBL] [Abstract][Full Text] [Related]
28. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
29. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract][Full Text] [Related]
30. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
Smith AJ; Dai H; Correia C; Takahashi R; Lee SH; Schmitz I; Kaufmann SH
J Biol Chem; 2011 May; 286(20):17682-92. PubMed ID: 21454712
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
33. Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.
Dal Col J; Mastorci K; Faè DA; Muraro E; Martorelli D; Inghirami G; Dolcetti R
Cancer Res; 2012 Apr; 72(7):1825-35. PubMed ID: 22311672
[TBL] [Abstract][Full Text] [Related]
34. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
35. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
[TBL] [Abstract][Full Text] [Related]
36. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
[TBL] [Abstract][Full Text] [Related]
37. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
38. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
39. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Jung HJ; Chen Z; McCarty N
Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Huang J; Ding T; Yang M; Liu H; Sun X; Jin J
Int J Hematol; 2011 Apr; 93(4):482-493. PubMed ID: 21451957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]